Updated single institution outcome data from the first-in-human CEND-1 trial in metastatic pancreatic cancer.

Andrew Dean,Fiona Mulligan,Geena Kelly,Emma Shaughnessy,Kate Wilson

Updated single institution outcome data from the first-in-human CEND-1 trial in metastatic pancreatic cancer.

2021

Andrew Dean
Fiona Mulligan
Geena Kelly
Emma Shaughnessy
Kate Wilson

e16274Background: In our phase I trial of the first-in-class agent CEND-1 with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer, we reported a preliminary overall RR of ...

Keywords:

Medicine
Gemcitabine
single institution
Internal medicine
Oncology
outcome data
first in human
in patient
Metastatic pancreatic cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations